Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054613 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
A Phase 2 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00054613 is a Phase 2 study that has completed, run by Mallinckrodt. The registered enrollment target is 72 participants.
The verdict
NCT00054613, a Phase 2 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
Interventions
- PROCEDURE Extracorporeal Photopheresis
- DRUG Methoxsalen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054613
The ClinicalTrials.gov registry entry for NCT00054613 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extracorporeal Photopheresis is the first listed.
NCT00054613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054613 about?
NCT00054613 is a clinical study titled "Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease". The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
What is the current status of trial NCT00054613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2002-06. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00054613?
The interventions under investigation include: Extracorporeal Photopheresis (PROCEDURE), Methoxsalen (DRUG).
Who is sponsoring clinical trial NCT00054613?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.